 | This article has multiple issues. Please help improve it or discuss these issues on the talk page . (Learn how and when to remove these template messages)
|
Boris Labar | |
|---|---|
| Born | 1947 (age 75–76) |
| Nationality | Croat |
Boris Labar (born 1947) is a Croatian physician and scientist in the field of hematology and hematopoietic stem cell transplantation.
Labar received a doctor of medicine degree in 1970 from the University of Zagreb School of Medicine. In the period from 1972 until 1976 he underwent specialization in internal medicine. In 1977, he took up the position of Assistant Professor at the Department of Internal Medicine at the University of Zagreb School of Medicine. In 1982 he received his Ph.D. degree from the University of Zagreb School of Medicine after defending the thesis entitled Pyruvate kinase in acute leukemia . [1]
In 1982 Labar with his team established the first bone marrow transplant (or HCT) program in South-Eastern Europe, at a time when such centers were rare even in the most developed countries. [2] From 1985-to 2012 Dr. Labar was the Head of the Division of Hematology. From 2000-2004 he was the Dean of the University of Zagreb School of Medicine. In 2005 he became Full Professor of Medicine at the aforementioned institution. In 2012 Dr. Labar retired from the University of Zagreb Medical Center “Rebro”. He continues to actively practice medicine in the private sector, currently at the Zagreb Clinic Center for Expert Medicine.
His research area is hematology, acute leukemia and lymphoma, with a focus on intensive chemotherapy and stem cell transplantation. Since 1974 Labar has published more than 405 scholarly articles, of which more than 100 appeared in Current Contents (CC) cited journals, with over 2000 citations.[ citation needed ]
| This section of a biography of a living person does not include any references or sources .(December 2020) |
Labar played a pivotal role in engaging Croatian hematology with the world. This process started in 1987 with the meeting “New Trends in Acute leukemia”, which he and his colleagues organized in Dubrovnik jointly with the European School of Oncology. For many years the Division of Hematology at the University of Zagreb has participated as a core member in the clinical trials of the European Organization for Research and Treatment of Cancer (EORTC) Leukemia Group. He and his team were also engaged in the European Blood and Marrow Transplant (EBMT) Acute Leukemia Working Party. During his mandate as Dean of the University of Zagreb School of Medicine (2000-2004), Dr. Labar introduced the first graduate curriculum in English language open to international candidates.
In 2009 Labar led the initiative resulting in the establishment of the Central and Eastern European Leukemia Group (CELG). He started and co-chaired the internationally renowned Leukemia and Lymphoma meeting “East meets West” in Croatia in September 2007 and 2011, which was organized in collaboration with the MD Anderson Cancer Center (Houston, Texas). For these services and his achievements in the international arena, in 2013 Dr. Boris Labar received the prestigious Center for International Blood and Marrow Transplant Research (CIBMTR) Distinguished Service Award.
Labar lives in Zagreb. He is married and has two sons.[ citation needed ]
Leukemia is a group of blood cancers that usually begin in the bone marrow and result in high numbers of abnormal blood cells. These blood cells are not fully developed and are called blasts or leukemia cells. Symptoms may include bleeding and bruising, bone pain, fatigue, fever, and an increased risk of infections. These symptoms occur due to a lack of normal blood cells. Diagnosis is typically made by blood tests or bone marrow biopsy.
Hematology is the branch of medicine concerned with the study of the cause, prognosis, treatment, and prevention of diseases related to blood. It involves treating diseases that affect the production of blood and its components, such as blood cells, hemoglobin, blood proteins, bone marrow, platelets, blood vessels, spleen, and the mechanism of coagulation. Such diseases might include hemophilia, sickle cell anemia, blood clots (thrombus), other bleeding disorders, and blood cancers such as leukemia, multiple myeloma, and lymphoma. The laboratory analysis of blood is frequently performed by a medical technologist or medical laboratory scientist.
Chronic lymphocytic leukemia (CLL) is a type of cancer in which the bone marrow makes too many lymphocytes. Early on, there are typically no symptoms. Later, non-painful lymph node swelling, feeling tired, fever, night sweats, or weight loss for no clear reason may occur. Enlargement of the spleen and low red blood cells (anemia) may also occur. It typically worsens gradually over years.
Hematopoietic stem-cell transplantation (HSCT) is the transplantation of multipotent hematopoietic stem cells, usually derived from bone marrow, peripheral blood, or umbilical cord blood in order to replicate inside of a patient and to produce additional normal blood cells. It may be autologous, allogeneic or syngeneic.
Edward Donnall "Don" Thomas was an American physician, professor emeritus at the University of Washington, and director emeritus of the clinical research division at the Fred Hutchinson Cancer Research Center. In 1990 he shared the Nobel Prize in Physiology or Medicine with Joseph E. Murray for the development of cell and organ transplantation. Thomas and his wife and research partner Dottie Thomas developed bone marrow transplantation as a treatment for leukemia.
John Edgar Dick is Canada Research Chair in Stem Cell Biology, Senior Scientist at the Princess Margaret Cancer Centre, University Health Network and Professor in the Department of Molecular Genetics at the University of Toronto in Canada. Dick is credited with first identifying cancer stem cells in certain types of human leukemia. His revolutionary findings highlighted the importance of understanding that not all cancer cells are the same and thus spawned a new direction in cancer research. Dick is also known for his demonstration of a blood stem cell's ability to replenish the blood system of a mouse, his development of a technique to enable an immune-deficient mouse to carry and produce human blood, and his creation of the world's first mouse with human leukemia.
Stephen Gould Emerson, M.D, Ph.D., was the 13th president of Haverford College from July 1, 2007, to August 10, 2011. In February 2012, he was appointed Director of the Herbert Irving Comprehensive Cancer Center at NewYork-Presbyterian Hospital/Columbia University Medical Center, and he will also hold the Clyde ’56 and Helen Wu Professorship in Immunology at the Columbia University Vagelos College of Physicians and Surgeons.
Robert Peter Gale is an American physician and medical researcher. He is known for research in leukemia and other bone marrow disorders.
Allen Charles Edward Eaves is the founding Director of the Terry Fox Laboratory for Hematology/Oncology Research, which over a 25-year period (1981–2006) he grew into an internationally recognized centre for the study of leukemia and stem cell research. His own research on chronic myelogenous leukemia (CML) has led the way to a new understanding of the disease. As Head of Hematology at the British Columbia Cancer Agency and the University of British Columbia for 18 years (1985–2003) he engineered the building of one of the first and largest bone marrow transplant programs in Canada. In recognition of his research accomplishments and leadership in moving basic science discoveries in stem cell biology into the clinic, he was elected President of the International Society of Cellular Therapy (1995–1997), Treasurer of the Foundation for the Accreditation of Cellular Therapy (1995–2002) and President of the American Society of Blood and Marrow Transplantation (1999–2000). In 2003 he was awarded the prestigious R. M. Taylor Medal by the Canadian Cancer Society and the National Cancer Institute of Canada.
George Quentin Daley is the Dean of the Faculty of Medicine, Caroline Shields Walker Professor of Medicine, and Professor of Biological Chemistry and Molecular Pharmacology at Harvard Medical School. He was formerly the Robert A. Stranahan Professor of Pediatrics at Harvard Medical School, Director of the Stem Cell Transplantation Program at Boston Children's Hospital, and an investigator of the Howard Hughes Medical Institute, Associate Director of Children's Stem Cell Program, a member of the Executive Committee of the Harvard Stem Cell Institute. He is a past president of the International Society for Stem Cell Research (2007–2008).
Georges Mathé was a French oncologist and immunologist. In November 1958, he performed the first successful allogeneic bone marrow transplant ever performed on unrelated human beings.
Expert Review of Hematology is a MEDLINE-indexed, peer-reviewed, international medical journal publishing review articles and original papers on all aspects of hematology. It is part of the Expert Review series, published by Informa.
Helen Elisabeth Heslop is a physician-scientist from New Zealand whose clinical interests are in hematopoietic stem cell transplants. Heslop’s research focuses on immunotherapy to treat viral infections, post transplant and hematologic malignancies. She is a professor in the Department of Medicine and Pediatrics at Baylor College of Medicine and the director of the Center for Cell and Gene Therapy at Baylor College of Medicine, Texas Children’s Hospital and Houston Methodist Hospital. She is also the Dan L. Duncan Chair and the associate director of clinical research at the Dan L. Duncan Cancer Center.
Steven Z. Pavletic is a Croatian-American physician and researcher in hematology and oncology known for his role in developing consensus guidelines for clinical trials in chronic Graft-versus-host disease (GVHD).
Roland Mertelsmann is a German hematologist and oncologist. He was a professor at the Freiburg University Medical Center, Department of Internal Medicine I (Oncology/Hematology). Mertelsmann is known for his scientific works in the fields of hematology, oncology, gene therapy and stem cell transplantation.
Guo Mei is a hematologist and associate director of 307th Hospital of Chinese People’s Liberation Army and deputy director of Radiation Research Institute.
Shimon Slavin is an Israeli professor of medicine. Slavin pioneered the use of immunotherapy mediated by allogeneic donor lymphocytes and innovative methods for stem cell transplantation for the cure of hematological malignancies and solid tumors, and using hematopoietic stem cells for induction of transplantation tolerance to bone marrow and donor allografts.
Martin Körbling is a German-American internist and hematologist, university professor, medical researcher and pioneer of blood stem cell transplantation.
Nirali N. Shah is an American physician-scientist and pediatric hematologist-oncologist, serving as head of the hematologic malignancies section of the pediatric oncology branch at the National Cancer Institute. She researches the translation of immunotherapeutic approaches to treat high-risk hematologic malignancies in children, adolescents and young adults.
Bob Löwenberg is a clinical hematologist/investigator. He is Professor of Hematology at Erasmus University Rotterdam.